JW Therapeutics 药明巨诺
Become an Innovation Leader in Cell Immunotherapy 以创新为先导，成为细胞免疫治疗引领者
Become an Innovation Leader in Cell Immunotherapy 以创新为先导，成为细胞免疫治疗引领者
JW Therapeutics 药明巨诺 is an innovative biotech company established in 2016 with a focus on the latest clinical cell therapy technology. The company is committed to developing, transforming, and promoting breakthrough cell-based immunotherapies to improve the lives of cancer patients and bring new hope. Co-founded by WuXi AppTec and Juno Therapeutics in February 2016, JW Therapeutics has garnered significant attention and support.
With its significant $100.00M Series B investment on 11 June 2020, the company has attracted a consortium of notable investors including Arch Venture Partners, Mirae Asset, Temasek Holdings, Citic PE, Loyal Valley Capital, Oriza Holdings, Sequoia China, WuXi AppTec, Juno Therapeutics, and CR-CP Life Science Fund.
Operating in the Biotechnology and Health Care industries, JW Therapeutics pioneers to become an innovation leader in cell immunotherapy, aiming to revolutionize the treatment of cancer and positively impact patient outcomes globally from its headquarters in China.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $100.00M | 10 |
|
11 Jun 2020 |
| Series A | $90.00M | - | 07 Mar 2018 | |
| Venture Round | Unknown | - | 01 Feb 2018 |
No recent news or press coverage available for JW Therapeutics 药明巨诺.
We care about your data, and we'd love to use cookies make your experience better.
